Patients undergoing keen and hip surgeries are more susceptible for developing deep vein thrombosis and then to pulmonary embolism which may develop in to life threatening stroke, because of the surgical procedures the patients undergoing hip and knee replacement surgeries are more susceptible to develop thrombosis. Thromboembolism poses great risk to patient towards stroke, therefore after such surgeries patients are required to be treated with anticoagulant therapies.
US FDA approved first drug which is a direct inhibitor of factor Xa , the molecule name of the molecule is Rivaroxaban and its brand name is Xarelto it is marketed in united states by Janssen Pharmaceuticals.
The drug Xarelto (rivaroxaban) is a first oraly taken inhibitor of factor xa, ( factor X a is an enzyme in the blood coagulation path way it act up on prothrombin and convert prothrombin to thrombin also see here.
Drug Xarelto is a once a day pill the pill is recommended for 12 days for patients under going knee replacement and for patient it is given for 35 days.
Other FDA approved drugs which are used as anticoagulants are as follows
Coumadin (warfarin), Heparin, Lovenox (enoxaparin), generic versions of enoxaparin, Arixtra (fondaparinux), Fragmin (dalteparin) only for hip replacement sergery.
Side effects observed with Xarelto is excessive bleeding, which is one of the common side effect associated with all anticoagulant drugs.
What is blow fill seal technology in sterile dosage form